Mode
Text Size
Log in / Sign up

Sex and gender differences impact heart failure symptoms, quality of life, and treatment accessWomen with Heart Failure May Experience Higher Symptom Burden

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize sex-specific symptom burdens and lower rates of optimal therapy in women with heart failure.

This guideline review explores the impact of sex and gender on heart failure management, specifically focusing on phenotype differences, biomarker profiles, pharmacologic responses, and access to device-based therapies. The authors synthesize evidence regarding how these factors influence patient outcomes and treatment pathways.

Key findings indicate that women report a greater symptom burden and poorer quality of life compared to men. Furthermore, the review highlights that women have lower use of optimal medical or device therapy, including guideline-directed medical therapy and device-based interventions. Regarding pharmacologic response, the authors note that women may achieve comparable therapeutic benefit at lower medication doses due to pharmacokinetic and pharmacodynamic differences.

A significant limitation noted is that most existing evidence and current guidelines are based on predominantly male cohorts. The review emphasizes that recognizing biological and sociocultural distinctions is essential for precision and equity in care. Addressing these gaps can improve diagnostic accuracy, optimize therapeutic strategies, and ensure more equitable cardiovascular care for all patients.

How this fits prior evidence

This guideline addresses a gap in the existing evidence by highlighting sex-specific disparities in heart failure management. While previous coverage has established that GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios, this review specifically focuses on how gender-related differences in symptoms, pharmacologic response, and access to device-based therapies impact outcomes for women in heart failure.

A review of heart failure care highlights significant differences in how the condition affects men and women. The findings show that women often experience a higher burden of symptoms and a lower quality of life compared to men with the same condition. These differences may be linked to biological and sociocultural factors.

While many current medical guidelines are sex-neutral, the review notes that most existing data comes from studies involving mostly men. This can make it harder for doctors to provide precise care for women. The report also suggests that because of differences in how bodies process medicine, women might achieve similar health benefits at lower medication doses.

Because current evidence is limited by a lack of diverse study groups, these findings are not intended to change immediate treatment plans. However, the review emphasizes that recognizing sex-specific needs is important for improving diagnosis and ensuring all patients get equal care. Patients should talk to their doctors about how these factors might affect their specific treatment plan.

What this means for you:
Women with heart failure may experience more symptoms and receive less optimal therapy than men.

Common questions

How do symptoms differ between men and women with heart failure?

The review indicates that women with heart failure often report a greater burden of symptoms compared to men. Additionally, women in these studies reported a poorer quality of life. These findings suggest that the experience of the disease may differ based on sex and gender.

Are there differences in how medication works for women?

The review suggests that women might achieve similar therapeutic benefits at lower medication doses than men. This is due to differences in pharmacokinetics and pharmacodynamics, which affect how the body processes and responds to specific medications.

Do women receive the same treatments as men for heart failure?

The findings show that women have a lower use of optimal medical or device therapy. This includes less frequent use of guideline-directed medical therapy and fewer device-based interventions compared to men.

Study Details

Study typeGuideline
EvidenceLevel 5
PublishedJul 2026
View Original Abstract ↓
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, affecting women and men in nearly equal numbers, yet important sex- and gender-related differences remain insufficiently recognized in clinical practice and research. Biological sex and gender influences profoundly the disease development, clinical presentation, diagnosis and management. For decades, most evidence and guideline recommendations have been based on predominantly male cohorts, limiting their applicability to women. This review aims to synthesize the current evidence on sex- and gender-related differences in HF. Also, it integrates data from experimental studies, clinical trials, large registries, and recent guidelines, emphasizing differences in phenotype, biomarker profiles, pharmacologic responses, and access to device-based therapies. Despite better survival, women report greater symptom burden, poorer quality of life, and lower use of optimal medical or device therapy, including lower use of guideline-directed medical therapy and device-based interventions. Pharmacokinetic and pharmacodynamic differences suggest that women may achieve comparable therapeutic benefit at lower medication doses, yet guidelines remain largely sex-neutral. Thus, recognizing these biological and sociocultural distinctions is essential for precision and equity in care, improving diagnostic accuracy, optimizing therapeutic strategies and ensuring equity in cardiovascular care, advancing truly individualized cardiovascular medicine.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.